重视抗血管内皮生长因子药物对早产儿视网膜病变患儿神经发育的影响

Pay attention to the effect of anti-vascular endothelial growth factor drugs on neurodevelopment in children with retinopathy of prematurity

早产儿视网膜病变(ROP)是引起儿童视力障碍的主要原因之一。随着人们对ROP发病机制研究的不断深入,抗血管内皮生长因子(VEGF)药物及临床应用使ROP的治疗模式发生了转变,因其治疗便捷、疗效明确的优势,已成为ROP的一种重要治疗方法。由于ROP患儿存在各器官功能发育不全,玻璃体腔注射抗VEGF药物可进入血液循环一过性地降低血液中VEGF水平,理论上可能会对ROP患儿各器官(尤其大脑)发育造成不良影响。因此,应重视抗VEGF药物对ROP患儿神经发育的影响,严格把握其适应证,规范其临床应用,不断提高ROP的总体疗效。

Retinopathy of prematurity(ROP)is one of the leading causes of visual impairment in children.As understanding on the pathogenesis of ROP accumulated,anti-vascular endothelial growth factor(VEGF)drugs and their application have changed the treatment mode.Anti-VEGF therapy,with convenient operation and clear efficacy,has become an important treatment method for ROP.However,due to the dysfunction of organs in children with ROP,anti-VEGF drugs can enter blood circulation after intravitreal injection and then lead to temporarily reduction of the VEGF level in the blood,which may theoretically cause adverse effects on the development of all organs(especially the brain)in children with ROP.Therefore,it's necessary to pay attention to the effect of anti-VEGF drugs on neurodevelopment in children with ROP,strictly grasp the indications,and standardize its clinical application,so as to continuously improve the overall prognosis of ROP.